KR102138852B1 - 주사용 제제 - Google Patents

주사용 제제 Download PDF

Info

Publication number
KR102138852B1
KR102138852B1 KR1020147032714A KR20147032714A KR102138852B1 KR 102138852 B1 KR102138852 B1 KR 102138852B1 KR 1020147032714 A KR1020147032714 A KR 1020147032714A KR 20147032714 A KR20147032714 A KR 20147032714A KR 102138852 B1 KR102138852 B1 KR 102138852B1
Authority
KR
South Korea
Prior art keywords
salt
preparation
injection
suspending agent
aripiprazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020147032714A
Other languages
English (en)
Korean (ko)
Other versions
KR20150003861A (ko
Inventor
다이키 카네코
타카쿠니 마츠다
유스케 호시카
Original Assignee
오쓰까 세이야꾸 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48614096&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102138852(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 오쓰까 세이야꾸 가부시키가이샤 filed Critical 오쓰까 세이야꾸 가부시키가이샤
Priority to KR1020207015451A priority Critical patent/KR102498075B1/ko
Publication of KR20150003861A publication Critical patent/KR20150003861A/ko
Application granted granted Critical
Publication of KR102138852B1 publication Critical patent/KR102138852B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020147032714A 2012-04-23 2013-04-23 주사용 제제 Active KR102138852B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020207015451A KR102498075B1 (ko) 2012-04-23 2013-04-23 주사용 제제

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261636938P 2012-04-23 2012-04-23
US61/636,938 2012-04-23
US201361792089P 2013-03-15 2013-03-15
US61/792,089 2013-03-15
PCT/JP2013/062683 WO2013162048A1 (en) 2012-04-23 2013-04-23 Injectable preparation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020207015451A Division KR102498075B1 (ko) 2012-04-23 2013-04-23 주사용 제제

Publications (2)

Publication Number Publication Date
KR20150003861A KR20150003861A (ko) 2015-01-09
KR102138852B1 true KR102138852B1 (ko) 2020-07-28

Family

ID=48614096

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020217029406A Ceased KR20210116702A (ko) 2012-04-23 2013-04-23 주사용 제제
KR1020247015029A Ceased KR20240068788A (ko) 2012-04-23 2013-04-23 주사용 제제
KR1020147032714A Active KR102138852B1 (ko) 2012-04-23 2013-04-23 주사용 제제
KR1020207015451A Active KR102498075B1 (ko) 2012-04-23 2013-04-23 주사용 제제

Family Applications Before (2)

Application Number Title Priority Date Filing Date
KR1020217029406A Ceased KR20210116702A (ko) 2012-04-23 2013-04-23 주사용 제제
KR1020247015029A Ceased KR20240068788A (ko) 2012-04-23 2013-04-23 주사용 제제

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020207015451A Active KR102498075B1 (ko) 2012-04-23 2013-04-23 주사용 제제

Country Status (31)

Country Link
US (9) US20150093442A1 (enExample)
EP (2) EP3539534A1 (enExample)
JP (7) JP6234996B2 (enExample)
KR (4) KR20210116702A (enExample)
CN (3) CN104470499B (enExample)
AR (1) AR090776A1 (enExample)
AU (6) AU2013253374B2 (enExample)
BR (1) BR112014026307B1 (enExample)
CA (2) CA3120297A1 (enExample)
CO (1) CO7151500A2 (enExample)
CY (1) CY1122252T1 (enExample)
DK (1) DK2841054T4 (enExample)
EA (1) EA026619B1 (enExample)
ES (1) ES2743706T5 (enExample)
HR (1) HRP20191366T4 (enExample)
HU (1) HUE045979T2 (enExample)
IL (1) IL235299B (enExample)
JO (2) JOP20200109A1 (enExample)
LT (1) LT2841054T (enExample)
MX (2) MX359241B (enExample)
MY (3) MY198007A (enExample)
NZ (1) NZ630335A (enExample)
PH (2) PH12014502379A1 (enExample)
PL (1) PL2841054T5 (enExample)
PT (1) PT2841054T (enExample)
SG (3) SG10201608753UA (enExample)
SI (1) SI2841054T2 (enExample)
TW (6) TW202126303A (enExample)
UA (1) UA115444C2 (enExample)
WO (1) WO2013162048A1 (enExample)
ZA (1) ZA201407335B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
TWI562991B (en) * 2012-04-23 2016-12-21 Otsuka Pharma Co Ltd Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same
AR090775A1 (es) * 2012-04-23 2014-12-03 Otsuka Pharma Co Ltd Preparado inyectable
CN105461703B (zh) * 2014-12-29 2019-05-17 深圳市泛谷药业股份有限公司 一种brexpiprazole的制备方法
JP6513461B2 (ja) * 2015-04-14 2019-05-15 帝國製薬株式会社 ブレクスピプラゾールの経皮吸収製剤
CN104829603A (zh) * 2015-05-19 2015-08-12 杭州新博思生物医药有限公司 A晶型依匹唑派盐酸盐及其制备方法
US10501450B2 (en) 2016-02-01 2019-12-10 Hexal Ag Anhydrate-free polymorphically pure micronized crystalline brexpiprazole di-hydrate for use in intramuscular injectable sustained release formulations
US11235976B2 (en) * 2017-01-26 2022-02-01 Sichuan Yingrui Pharmaceutical Technology Company Nanocarbon-iron composite system as well as composition, preparation method and use thereof
WO2019213286A1 (en) * 2018-05-02 2019-11-07 LifeMax Laboratories, Inc. Extended release suspension formulation of lurasidone
WO2020089942A2 (en) * 2018-11-02 2020-05-07 Amaterasu Lifesciences Llp A liquid injectable composition
WO2021199076A1 (en) * 2020-03-30 2021-10-07 Cipla Limited Injectable aripiprazole formulation
HRP20241574T1 (hr) * 2020-04-01 2025-01-31 Otsuka Pharmaceutical Co., Ltd. Metode za početak doziranja liječenja aripiprazolom
WO2022093722A1 (en) * 2020-10-27 2022-05-05 Pts Consulting, Llc A liquid injectable composition of donepezil
US11229644B1 (en) * 2020-12-31 2022-01-25 Lake O'hara Llc Methods of treating psychiatric disorders in obese patients with brexpiprazole
US11910794B2 (en) 2021-03-08 2024-02-27 Monsanto Technology Llc Solutions and methods for long-term pollen storage
WO2023067664A1 (ja) * 2021-10-18 2023-04-27 大塚製薬株式会社 ベンゾチオフェン化合物の新規結晶形及びその製造方法
JP7760615B2 (ja) * 2022-06-16 2025-10-27 ウィズダム・ファーマスーティカル・カンパニー・リミテッド 薬物組成物及びブレクスピプラゾール口腔内溶解フィルム
CN115969785A (zh) * 2022-12-30 2023-04-18 辰欣药业股份有限公司 一种阿立哌唑注射剂及其制备方法
CA3197997A1 (en) * 2023-03-17 2025-01-23 Otsuka Pharmaceutical Co., Ltd. METHODS FOR DISPERSING INJECTABLE PREPARATIONS OF ARIPIPRAZOLE
TW202448470A (zh) 2023-04-26 2024-12-16 日商大塚製藥股份有限公司 用於以阿立哌唑治療思覺失調症或第一型雙極性疾患之劑量起始
WO2025051282A1 (zh) * 2023-09-08 2025-03-13 广州玻思韬控释药业有限公司 注射用凝胶
WO2025183016A1 (ja) * 2024-02-26 2025-09-04 大塚製薬株式会社 Ｑｕａｂｏｄｅｐｉｓｔａｔ含有組成物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012026562A1 (en) * 2010-08-24 2012-03-01 Otsuka Pharmaceutical Co., Ltd. Suspension and cake composition containing carbostyryl derivative and silicone oil and/or silicone oil derivative

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB864100A (en) * 1957-04-09 1961-03-29 Pfizer & Co C Therapeutic pencillin compositions and the preparation thereof
JPS5913714A (ja) 1982-07-13 1984-01-24 Taito Pfizer Kk 外用消炎鎮痛剤
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
US5192802A (en) 1991-09-25 1993-03-09 Mcneil-Ppc, Inc. Bioadhesive pharmaceutical carrier
JP4012994B2 (ja) 1996-05-08 2007-11-28 大塚製薬株式会社 抗不安薬
US20020076437A1 (en) 2000-04-12 2002-06-20 Sanjeev Kothari Flashmelt oral dosage formulation
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
AR032641A1 (es) 2001-01-29 2003-11-19 Otsuka Pharma Co Ltd Agonista de subtipo de receptor 5-ht 1a.
MY129350A (en) 2001-04-25 2007-03-30 Bristol Myers Squibb Co Aripiprazole oral solution
PE20030445A1 (es) * 2001-09-25 2003-07-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
JP2003171264A (ja) * 2001-12-07 2003-06-17 Taiyo Yakuhin Kogyo Kk マイクロカプセル及びその製造方法
JP2003238393A (ja) 2002-02-15 2003-08-27 Otsuka Pharmaceut Co Ltd 施錠性が改善された錠剤及びその製造方法
UA79984C2 (en) * 2002-08-20 2007-08-10 Bristol Myers Squibb Co Preparation on the basis of aripiprazole complex and use thereof
RU2356554C2 (ru) 2002-12-27 2009-05-27 Оцука Фармасьютикал Ко., Лтд. Производные карбостирила и ингибиторы обратного захвата серотонина для лечения эмоциональных расстройств
EP1480953B2 (en) 2003-01-09 2010-08-18 Otsuka Pharmaceutical Co., Ltd. Process for preparing aripiprazole
US7658998B2 (en) 2003-01-22 2010-02-09 Alkermes Controlled Therapeutics, Inc. Method of preparing sustained release microparticles
US20070110784A1 (en) * 2003-05-02 2007-05-17 Rimon Therapeutics Ltd. Thermally reversible implant
CN102000336A (zh) 2003-05-23 2011-04-06 大塚制药株式会社 用于治疗情感障碍的喹诺酮衍生物和情绪稳定剂
US6987111B2 (en) 2003-08-06 2006-01-17 Alkermes Controlled Therapeutics, Ii Aripiprazole, olanzapine and haloperidol pamoate salts
US20050032811A1 (en) 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
MXPA06004489A (es) * 2003-10-23 2006-06-20 Otsuka Pharma Co Ltd Formulacion y metodo de aripiprazol inyectable esteril de liberacion controlada.
TWI371274B (en) 2003-10-23 2012-09-01 Bristol Myers Squibb Co Process for making sterile aripiprazole of desired mean particle size
KR101148013B1 (ko) 2003-10-27 2012-07-05 다니스코 유에스 인크. 국소용 제제, 및 활성제를 기재로 전달하는 방법
WO2005070332A1 (en) 2004-01-12 2005-08-04 The Trustees Of The University Of Pennsylvania Long-term delivery formulations and methods of use thereof
JP2006219380A (ja) * 2005-02-08 2006-08-24 Minofuaagen Seiyaku:Kk グリチルリチン皮下注射製剤
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
CA2622758A1 (en) 2005-09-15 2007-03-29 Elan Pharma International, Limited Nanoparticulate aripiprazole formulations
EP1948271B1 (en) 2005-11-17 2013-10-02 Zogenix, Inc. Delivery of viscous formulations by needle-free injection
JP4373983B2 (ja) 2006-01-27 2009-11-25 三菱電機インフォメーションシステムズ株式会社 流通経路管理装置及び流通経路管理プログラム
GB0618879D0 (en) * 2006-09-26 2006-11-01 Zysis Ltd Pharmaceutical compositions
EA200970348A1 (ru) * 2006-10-05 2009-10-30 Панацея Биотек Лтд. Новые инъецируемые депо-композиции и способ получения таких композиций
JP4540700B2 (ja) 2006-10-13 2010-09-08 大塚製薬株式会社 医薬
WO2008090632A1 (en) 2007-01-26 2008-07-31 Otsuka Pharmaceutical Co., Ltd. Marker for detecting the proposed efficacy of treatment
RU2485941C2 (ru) 2007-06-25 2013-06-27 Оцука Фармасьютикал Ко., Лтд. Микросферы, имеющие структуру ядро/оболочка
PT2170279T (pt) * 2007-07-31 2018-04-06 Otsuka Pharma Co Ltd Métodos para produção de suspensão de aripiprazole e formulação liofilizada
CA2697160A1 (en) * 2007-08-21 2009-02-26 Harbor Biosciences, Inc. Stabilized therapeutic compositions and formulations
JP2011136906A (ja) 2008-04-18 2011-07-14 Otsuka Pharmaceut Co Ltd 複素環化合物
JP2009286740A (ja) 2008-05-30 2009-12-10 Otsuka Pharmaceut Co Ltd アリピプラゾールを含有する逆耐性抑制剤
TR200809200A1 (tr) * 2008-12-01 2009-12-21 Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� Meloksikam içeren farmasötik formülasyonlar
EP3167875A1 (en) 2009-05-27 2017-05-17 Alkermes Pharma Ireland Limited Reduction of flake-like aggregation in nanoparticulate meloxicam compositions
RU2555760C2 (ru) 2009-09-11 2015-07-10 Оцука Фармасьютикал Ко., Лтд. Терапевтический агент против хронической боли
EP2629775A4 (en) * 2010-10-18 2014-06-11 Dainippon Sumitomo Pharma Co INJECTABLE FORMULATION WITH DELAYED RELEASE
AR083884A1 (es) 2010-11-16 2013-03-27 Otsuka Pharma Co Ltd Jeringa prellenable de doble camara y relleno de aripiprazol en la jeringa
JP2012121850A (ja) 2010-12-09 2012-06-28 Otsuka Pharmaceut Co Ltd アリピプラゾールの経口速溶性組成物
LT2667856T (lt) 2011-01-24 2021-11-25 Otsuka Pharmaceutical Co., Ltd. Medicininė priemonė, kurioje yra sausos masės kompozicija, apimanti aripiprazolą kaip veikliąją sudedamąją dalį, ir sausos masės kompozicija, apimanti aripiprazolą kaip veikliąją sudedamąją dalį
TWI636784B (zh) 2011-04-05 2018-10-01 大塚製藥股份有限公司 含7-〔4-(4-苯並〔b〕噻吩-4-基-哌-1-基)丁氧基〕-1H-喹啉-2-酮之醫藥組成物與套組，以及彼之用途
JP2012232958A (ja) 2011-05-09 2012-11-29 Otsuka Pharmaceut Co Ltd 注射製剤
JO3410B1 (ar) 2011-06-07 2019-10-20 Otsuka Pharma Co Ltd تركيبة أريبيبرازول مجفف بالتبريد
CN102846543B (zh) * 2011-06-27 2014-11-19 上海中西制药有限公司 一种阿立哌唑药物制剂及其制备方法
TW201309651A (zh) 2011-06-29 2013-03-01 Otsuka Pharma Co Ltd 阿立哌唑（ａｒｉｐｉｐｒａｚｏｌｅ）無水物Ｂ形結晶微粒子之製造方法
KR101911121B1 (ko) 2011-07-28 2018-10-23 오쓰까 세이야꾸 가부시키가이샤 벤조［ｂ］티오펜 화합물의 제조 방법
JO3227B1 (ar) 2011-09-08 2018-03-08 Otsuka Pharma Co Ltd مشتقات بنزو ثيوفين بها استبدال ببرازين كعوامل مضادة للذهان
JO3753B1 (ar) 2011-10-14 2021-01-31 Otsuka Pharma Co Ltd قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه
TWI632921B (zh) 2011-10-19 2018-08-21 大塚製藥股份有限公司 口服溶液
JP2013139441A (ja) 2011-12-28 2013-07-18 Otsuka Pharmaceut Co Ltd マイクロスフェア
TW201332572A (zh) 2011-12-28 2013-08-16 Otsuka Pharma Co Ltd 具有經取代的β－環糊精之藥物製劑
TW201343201A (zh) 2012-03-06 2013-11-01 Otsuka Pharma Co Ltd 持續釋放型口服固體製劑
TWI562991B (en) 2012-04-23 2016-12-21 Otsuka Pharma Co Ltd Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same
JOP20200109A1 (ar) * 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
AR090775A1 (es) 2012-04-23 2014-12-03 Otsuka Pharma Co Ltd Preparado inyectable

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012026562A1 (en) * 2010-08-24 2012-03-01 Otsuka Pharmaceutical Co., Ltd. Suspension and cake composition containing carbostyryl derivative and silicone oil and/or silicone oil derivative

Also Published As

Publication number Publication date
PH12019500498A1 (en) 2020-03-02
CN108186556A (zh) 2018-06-22
US12016927B2 (en) 2024-06-25
US20200179517A1 (en) 2020-06-11
SI2841054T2 (sl) 2022-05-31
AR090776A1 (es) 2014-12-03
US20230390399A1 (en) 2023-12-07
US10517951B2 (en) 2019-12-31
TW201350136A (zh) 2013-12-16
AU2025200229A1 (en) 2025-01-30
TW202126303A (zh) 2021-07-16
DK2841054T3 (da) 2019-09-09
JP6234996B2 (ja) 2017-11-22
CO7151500A2 (es) 2014-12-29
AU2019200060A1 (en) 2019-01-31
EP2841054A1 (en) 2015-03-04
ES2743706T3 (es) 2020-02-20
CY1122252T1 (el) 2020-11-25
AU2013253374A1 (en) 2014-10-23
US20210085794A1 (en) 2021-03-25
TW202425992A (zh) 2024-07-01
AU2020204200A1 (en) 2020-07-16
TW202535396A (zh) 2025-09-16
AU2020204200B2 (en) 2022-06-30
UA115444C2 (uk) 2017-11-10
MX2014012811A (es) 2015-05-07
PL2841054T5 (pl) 2022-07-18
TW201900174A (zh) 2019-01-01
HK1206988A1 (en) 2016-01-22
JP2022050619A (ja) 2022-03-30
US11638757B2 (en) 2023-05-02
US20190336607A1 (en) 2019-11-07
TWI637752B (zh) 2018-10-11
US20190099494A1 (en) 2019-04-04
JP2015514751A (ja) 2015-05-21
JP2025041805A (ja) 2025-03-26
CA2869889A1 (en) 2013-10-31
KR20240068788A (ko) 2024-05-17
HK1257028A1 (zh) 2019-10-11
JP2019070028A (ja) 2019-05-09
AU2017228608A1 (en) 2017-10-05
KR20210116702A (ko) 2021-09-27
SI2841054T1 (sl) 2019-09-30
BR112014026307B1 (pt) 2022-10-11
EP3539534A1 (en) 2019-09-18
CN114344259B (zh) 2024-02-13
PH12014502379B1 (en) 2015-01-12
EP2841054B2 (en) 2022-04-06
CN114344259A (zh) 2022-04-15
LT2841054T (lt) 2019-09-10
BR112014026307A2 (pt) 2017-06-27
HRP20191366T1 (hr) 2019-12-27
US20150093442A1 (en) 2015-04-02
IL235299A0 (en) 2014-12-31
AU2022241491A1 (en) 2022-10-20
HRP20191366T4 (hr) 2022-08-19
CN108186556B (zh) 2022-06-10
US20220096638A1 (en) 2022-03-31
KR102498075B1 (ko) 2023-02-10
EA201491685A1 (ru) 2015-04-30
AU2022241491B2 (en) 2024-10-24
AU2013253374B2 (en) 2017-06-15
SG10201913425VA (en) 2020-03-30
JP2023113806A (ja) 2023-08-16
MY210484A (en) 2025-09-24
MY198007A (en) 2023-07-25
SG11201406451SA (en) 2014-11-27
TWI713826B (zh) 2020-12-21
AU2017228608C1 (en) 2019-02-21
ZA201407335B (en) 2019-06-26
US20250121065A1 (en) 2025-04-17
JO3632B1 (ar) 2020-08-27
PL2841054T3 (pl) 2019-10-31
CN104470499A (zh) 2015-03-25
NZ630335A (en) 2016-07-29
PH12014502379A1 (en) 2015-01-12
CN104470499B (zh) 2018-03-16
WO2013162048A1 (en) 2013-10-31
JP2018048179A (ja) 2018-03-29
KR20200064173A (ko) 2020-06-05
EP2841054B1 (en) 2019-06-26
JP6470378B2 (ja) 2019-02-13
JP2021008512A (ja) 2021-01-28
SG10201608753UA (en) 2016-12-29
MX359241B (es) 2018-09-20
ES2743706T5 (es) 2022-05-25
TW202313036A (zh) 2023-04-01
JP7612758B2 (ja) 2025-01-14
MY178573A (en) 2020-10-16
KR20150003861A (ko) 2015-01-09
US11097007B2 (en) 2021-08-24
PT2841054T (pt) 2019-09-09
CA2869889C (en) 2021-07-20
JP7293412B2 (ja) 2023-06-19
AU2017228608B2 (en) 2018-10-18
JOP20200109A1 (ar) 2017-06-16
IL235299B (en) 2019-12-31
EA026619B1 (ru) 2017-04-28
US20180055941A1 (en) 2018-03-01
CA3120297A1 (en) 2013-10-31
HUE045979T2 (hu) 2020-01-28
DK2841054T4 (da) 2022-06-13
MX387891B (es) 2025-03-19

Similar Documents

Publication Publication Date Title
KR102138852B1 (ko) 주사용 제제
HK1206988B (en) Injectable preparation

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20141121

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20180416

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190930

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20200427

PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20200528

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20200629

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20200722

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20200722

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20240619

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20250616

Start annual number: 6

End annual number: 6